Archived Article This article was published more than 5 months ago. The market data, prices, forecasts, and analysis were accurate at the time of publication but may have changed since then. Please use this article for historical reference only and refer to our latest content for current market information.
- Cassava sciences records a 46% gain for the week as it presents data for its new blood test and treatment for Alzheimer's disease.
Cassava sciences stock price is down 6.91% as traders look to bank profits made on the stock this week.
The company announced new data for testing and treatment of Alzheimer’s disease, sending its stocks soaring by 29.5% in midweek trading. Cassava Sciences is developing a revolutionary blood test (SavaDx) for detecting Alzheimer’s disease and Simufilam, a new treatment for the debilitating illness. Data will be presented on 26 July and 29 July.
Despite today’s correction, Cassava Sciences is up 46.24% as of writing.
Cassava Sciences Stock Price Outlook
Price is now testing the 4 February high at 117.12. A breakdown of this area brings the 112.88 support (50% Fibonacci extension and 9 July high) into the picture. Any further declines in price have to take out 103.34 and 95.75, targeting the 90.00 psychological support and 3 February high.
A bounce on the present support or any of the subsequent support levels below ultimately needs to take out the present all-time high at 130.47 to aim for potential new highs at 136.00 (78.6% Fibonacci extension) and 144.09 (88.6% Fibonacci extension).
Cassava Sciences: Daily Chart
